Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678969 | 0.94 | GNRHR (0.77) | GNRHR | |
| SCHEMBL4677608 | 0.86 | GNRHR (0.76) | GNRHRCYP3A4 | |
| SCHEMBL5762494 | 0.81 | GNRHR (0.73) | GNRHRCYP3A4 | |
| SCHEMBL4677980 | 0.81 | GNRHR (0.76) | GNRHRCYP3A4 | |
| SCHEMBL4677984 | 0.81 | GNRHR (0.76) | GNRHRCYP3A4 | |
| SCHEMBL5002174 | 0.79 | GNRHR (0.66) | GNRHRCYP3A4 | |
| SCHEMBL30354401 | 0.78 | GNRHR (0.74) | GNRHRCYP3A4 | |
| SCHEMBL22716575 | 0.77 | GNRHR (0.75) | GNRHRCYP3A4 | |
| SCHEMBL22716571 | 0.77 | GNRHR (0.75) | GNRHRCYP3A4 | |
| SCHEMBL20547876 | 0.77 | GNRHR (0.78) | GNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646389-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2008-09-10 | — | — | EP | claimed |
| US-7176211-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-13 | — | — | US | claimed |
| US-20060122202-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-06-08 | — | — | US | claimed |
| US-7056927-B2 | 3-[2(R)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione; utility in treatment of a variety of sex-hormone related conditions in both men and women | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-06-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122202-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.